AC ImmuneACIU +4.70%26 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ACIU with a GF Score™ of 26/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, AC Immune ranks worse than 84.05% on this metric.
The historical rank and industry rank for AC Immune's OCF Margin % or its related term are showing as below:
ACIU'
s OCF Margin % Range Over the Past 10 Years
Min: -1938.31 Med: -385.7 Max: 241.1
Current: -1818.79
During the past 12 years, the highest OCF Margin % of AC Immune was 241.10%. The lowest was -1938.31%. And the median was -385.70%.
ACIU's OCF Margin % is ranked worse than 84.05% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs ACIU: -1818.79
AC Immune OCF Margin % Related Terms
AC Immune OCF Margin % Historical Data
* Premium members only.
The historical data trend for AC Immune's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AC Immune's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AC Immune OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AC Immune's OCF Margin % distribution charts can be found below:
* The bar in red indicates where AC Immune's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AC Immune (ACIU) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AC Immune and its competitors. According to the industry distribution chart, AC Immune ranks #806 out of 959 companies in the Biotechnology industry, placing it in the top 84%.
Is AC Immune's OCF Margin % too high?
AC Immune's current OCF Margin % is 0.00%. Based on the distribution chart, AC Immune ranks #806 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AC Immune has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's OCF Margin % compare to TRDA and MGNX?
According to the Biotechnology industry distribution chart, AC Immune ranks #806 out of 959 companies for OCF Margin %. This places AC Immune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AC Immune and its competitors. AC Immune's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.56 — trading 241.3% above its estimated fair value. The current OCF Margin % is 0.00%. AC Immune's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For AC Immune (ACIU), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AC Immune (ACIU) Overvalued in 2026?
Based on GuruFocus' analysis, AC Immune stock appears to be overvalued.
The current stock price of $2.56 is trading 241.3% above its estimated GF Value™ of $0.75.
GuruFocus considers AC Immune to be Significantly Overvalued.
Key valuation signals for ACIU:
OCF Margin %: 0.00%
GF Value™: $0.75 vs. price of $2.56 (241.3% above fair value)
No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score
Get the complete analysis for ACIU
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIU has been successfully added to your 
